InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (12 ops.)
Insider track record
CFODisclosed buys
0
Disclosed sells
12
T+90 hit rate
0%
T+90 mean return
-39.0%
Across 6 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by Mason Michael, Chief Financial Officer. Officer active across 1 company, notably Karyopharm Therapeutics Inc.. Aggregated, 18 filings have been published. Split: 0 buy · 12 sells. Total volume traded: €147k. Activity tracked since 1 June 2021. The latest transaction was disclosed on 4 September 2024 (Cession). Regulator: SEC (Form 4). The full history is openly available.
Declarations18 total
7,050 shares@ US$0.72183.1% of flowCommon StockSEC:0000950170-24-104031:0
652 shares@ US$0.990.4% of flowCommon StockSEC:0000950170-24-069860:0
27,687 shares@ US$1.1720.4% of flowCommonSEC:0000950170-24-025191:0
2,545 shares@ US$1.32382.1% of flowCommon StockSEC:0000950170-24-023292:0
4,205 shares@ US$1.58654.2% of flowCommon StockSEC:0000950170-24-012832:0
13,333 shares0Common StockSEC:0000950170-24-007588:0
6,913 shares@ US$1.33135.8% of flowCommon StockSEC:0001209191-23-048162:0
631 shares@ US$2.220.9% of flowCommon StockSEC:0001209191-23-034262:0
95,000 shares0Common StockSEC:0001209191-23-014843:0
2,802 shares@ US$3.03685.5% of flowCommon StockSEC:0001209191-23-014078:0
4,141 shares@ US$3.408.9% of flowCommon StockSEC:0001209191-23-007775:0
30,000 shares0Common StockSEC:0001209191-22-048394:0
598 shares@ US$6.040.0019% mcap4.7% of flowCommon StockSEC:0000899243-22-021234:0
88,200 shares0Common StockSEC:0001209191-22-014628:0
3,947 shares@ US$9.8620.020% mcap100.0% of flowCommon StockSEC:0001209191-22-008126
3,947 shares@ US$9.8620.020% mcap47.6% of flowCommon StockSEC:0001209191-22-008126:0
5,500 shares0Common StockSEC:0000899243-21-021368:0
5,500 shares0Common StockSEC:0000899243-21-021368
18 of 18 declarations
About Mason Michael
Michael Mason is the Chief Financial Officer at Karyopharm Therapeutics Inc. In this role, he oversees the company's financial operations and participates in overall strategy. Karyopharm Therapeutics Inc. is a biopharmaceutical company specializing in developing innovative treatments. Michael Mason brings valuable financial expertise to support the company's growth and sustainability.
